About Glimepiride API
Therapeutic CategoryAnti-Diabetic
CAS Number
93479-97-1
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, CEP Submitted
Mechanism of Action
Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
Indication
AMARYL is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Important Limitations of Use:
- Not for treating type 1 diabetes mellitus or diabetic ketoacidosis
Related APIs
Dapagliflozin (Amorphous)
Anti-Diabetic
Dapagliflozin (PG Solvate Monohydrate)
Anti-Diabetic
Glimepiride
Anti-Diabetic
Linagliptin
Anti-Diabetic
Liraglutide
Anti-Diabetic
Pioglitazone Hydrochloride
Anti-Diabetic
Sitagliptin Hydrochloride
Anti-Diabetic
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!